Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003092583A2 Methods and compositions for treating ectoparasite infestation
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003072090A3 Use of tyrosine kinase inhibitors for treating cns disorders
11/13/2003WO2003068968A3 Mutated gene coding for a lat protein and the biological applications thereof
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003066001A3 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
11/13/2003WO2003063822A3 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
11/13/2003WO2003063821A3 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
11/13/2003WO2003061553A3 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
11/13/2003WO2003057688A3 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
11/13/2003WO2003057672A3 Tetrahydroquinoline analogues as muscarinic agonists
11/13/2003WO2003053966A3 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
11/13/2003WO2003053331A3 Protease inhibitors
11/13/2003WO2003042113A8 Production of cell suspensions
11/13/2003WO2003035008A3 Functionalized stilbene derivatives as improved vascular targeting agents
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029221A8 Tetrahydroisochinolines, their production and the use thereof as analgesics
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003028727A9 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
11/13/2003WO2003028536A3 Methods for diagnosing and treating heart disease
11/13/2003WO2003024448A3 Inhibitors of histone deacetylase
11/13/2003WO2003022871A3 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003017921A3 A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes
11/13/2003WO2003015780A3 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
11/13/2003WO2003013586A8 Access control system
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003000889A3 Identification of ses-1 and the uses of the same
11/13/2003WO2002098849A3 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002072888A3 Polymorphisms in the human cmoat gene and uses thereof
11/13/2003WO2002072031A3 Substituted tetracycline compounds as synergistic antifungal agents
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002057231A8 Benz(g) indoles and their use as spla2 inhibitors
11/13/2003WO2002050030A8 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
11/13/2003WO2002050029A8 Tetracyclic derivatives as spla2 inhibitors
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003WO2002032868A8 2-substituted heterocyclic compounds and their use in treating multidrug resistance
11/13/2003WO2002018278A8 Method and apparatus for preparing aqueous dispersion of ultra-fine active carbon particles
11/13/2003WO2001040188A8 Curcumin analogues for treating cancer
11/13/2003WO2000021978A3 Laminin 5, 13 and 14 and uses thereof
11/13/2003US20030212276 Process for the preparation of 7-substituted-3 quinolinecarbonitriles
11/13/2003US20030212272 Vasodilation; hypotensive agents; cardiovascular disorders
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212266 Growth arrest homeobox gene
11/13/2003US20030212141 Serotonin antagonists
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212128 Crystalline particles of escitalopram oxalate having a median particle size of >40 mu m; cystallization by gradually cooling the solution of dissolved escitalopram oxalate at a controlled cooling rate; adding crystals of escitalopram oxalate and holding; isolating particles
11/13/2003US20030212115 Remedies for inflammatory bowel diseases
11/13/2003US20030212100 Antidiabetic agnets; insulin resistance
11/13/2003US20030212097 Osteoporosis, antiarthrtic agents; antitumor agents
11/13/2003US20030212096 Analgesics, antiinflammatory agents, autoimmune disease, viricides, bactericides, antitumor agents, organ grafting, central nervous system disorders
11/13/2003US20030212094 Novel cyclic amide derivatives
11/13/2003US20030212093 Imidazonaphthyridines
11/13/2003US20030212091 Aryl ether substituted imidazoquinolines
11/13/2003US20030212088 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/13/2003US20030212087 Plant extracts; antitumor, anticancer agents; topoisomerase inhibitor
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212080 Adenosine A2a receptor antagonists
11/13/2003US20030212079 Antiischemic agents; central nervous system disorders
11/13/2003US20030212074 Phosphate transport inhibitors
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212069 Antithrombotic amides
11/13/2003US20030212068 Antiinflammatory agents; antiallergens; antiarthritic agents
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212066 1-Sulfonyl pyrrolidine derivatives
11/13/2003US20030212064 Triazolotriazinones and the use thereof
11/13/2003US20030212062 Morpholinone and morpholine derivatives and uses thereof
11/13/2003US20030212059 Adenosine A2a receptor antagonists
11/13/2003US20030212058 Side effect reduction; osteoporosis therapy
11/13/2003US20030212057 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
11/13/2003US20030212048 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
11/13/2003US20030212032 Oligonucleotide N3'→P5' thiophosphoramidates: their synthesis and use
11/13/2003US20030212024 Compositions and methods for cell dedifferentiation and tissue regeneration
11/13/2003US20030212012 Prevention labor contraction; urogenital disorders
11/13/2003US20030212008 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
11/13/2003US20030212004 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
11/13/2003US20030211997 Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same
11/13/2003US20030211995 Therapy for drug resistance bacteria
11/13/2003US20030211993 Control cell proliferation, cell differentiation; culture product
11/13/2003US20030211969 Administering activated protein c; controlling blood coagulation
11/13/2003US20030211964 Method of inhibiting pathogenicity of infectious agents
11/13/2003US20030211608 Antisense modulation of glycogen synthase kinase 3 beta expression
11/13/2003US20030211607 Antisense modulation of survivin expression
11/13/2003US20030211583 Egs molecules that specifically downregulae bcl-xl experession
11/13/2003US20030211577 Novel G protein-coupled receptor, GAVE7
11/13/2003US20030211542 Assays and methods of diagnosis and treatment based on use of sodium channels as targets for amyloid beta or its aggregates
11/13/2003US20030211540 Treatment of insulin resistance
11/13/2003US20030211529 Human Eag2
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211180 Viricides, anticancer agents; side effect reduction
11/13/2003US20030211176 Using plant extract; hot water extraction
1 ... 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 ... 1564